Here, we designed a CPE peptide-conjugated, CLDN4-binding liposome for pancreatic cancer-targeted therapy employing a 17-amino acid CPE peptide (CPE17; NSSYSGNYPYSILFQKF). This evidence concerns the gene CLDN4 and familial pancreatic carcinoma.